Cambridge headquartered global pharmaceutical company AstraZeneca took its spending on China plays in the last month to ...

Under terms of the deal, CSPC will receive $110 million upfront, with potential milestone payments reaching up to $5.22 ...

AstraZeneca has signed an AI-led research agreement with China’s CSPC Pharmaceutical Group worth up to $5.3 billion, which ...

This trial evaluated the safety, tolerability, pharmacodynamics, pharmacokinetics and clinical activity of AstraZeneca’s ...

AstraZeneca (AZ) and CSPC Pharmaceuticals Group have entered into a partnership worth up to $5.3bn to develop therapies for ...

Growth is driven by the increasing prevalence of neurological disorders like Alzheimer's, Parkinson's, and schizophrenia, ...

Trump's NIH cuts are gutting university labs that fuel Big Pharma's drug pipeline and pushing U.S. biotech jobs, research, ...

While cancelled NIH grants and regulatory uncertainty are less hospitable to clinical research in the U.S., Europe must play ...

AstraZeneca is making a bold move. The drug giant just teamed up with CSPC in a deal worth up to $5.3 billion. The goal? To ...

Day One officially began on Monday, June 15, 2025, with an automation session chaired by LCGC International’s Pharmaceutical Perspectives columnist, and active member of ChromSoc, Adrian Clarke from ...

The FTSE 100 was up 0.2 per cent after the first hour of trading, having finished on a record high of 8,871.31 on Thursday.

This single-arm, multicenter Phase II study assessed the efficacy and safety of olverembatinib in combination with the VP (vindesine+prednisone) regimen (OVP) in the first-line treatment of adult ...